ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics. Volume 2

Macaulay Amechi Onuigbo, MD (Editor)
College of Medicine, Mayo Clinic, Rochester, MN, USA

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

This book, published in two volumes, Volume 1 and Volume 2, respectively, represents the most comprehensive and up-to-date collection of current literature on angiotensin inhibition and related topics in medicine, nephrology and cardiovascular medicine ever compiled. Top experts in the various fields of nephrology, hypertension, cardiovascular medicine, pharmacotherapeutics and related fields from all five continents have contributed essays, original papers, reviews and editorial opinions in this volume.

This book has turned out to be the most authoritative reference source on ACEIs, with contributions made by leading experts in their various fields of medicine, from the USA, Europe, including the United Kingdom, South America, Australia-New Zealand, Asia including Japan, and Africa. Critically vital clinical topics are covered in this book by top world-renowned experts in different subspecialties, including classic topics such as the efficacy of ACE inhibition as an antihypertensive among the various ethnicities and races, as written from American, African, Caribbean and European perspectives

This volume should indeed serve as a major literature reference text for physicians in general, internists, researchers, cardiologists and hypertension specialists, and especially the practitioners of the art of nephrology in all the countries around the world. Medical students and various physician training programs should reach for a copy of this volume as a research and teaching tool for many years to come. There is also a place here for research scientists in the pharmaceutical industry to review current and newly emerging indications for angiotensin inhibition and the future of reno-protection. (Imprint: Nova Biomedical )

Special Preview
Zbylut J. Twardowski, MD PhD FACP

Foreword
Richard J. Glassock, MD MACP

Preface

Acknowledgements

Cognitive Drift Poem

Section 1. ACE Inhibitors and Angiotensin Receptor Blockers in Hypertension

Chapter 1 - Chronotherapy of Hypertension with ACEIs and CKD: A New Solution to an Old Problem (pp. 3-40)
Ramón C. Hermida, PhD, Diana E. Ayala, MD, MPH, PhD, Michael H. Smolensky, PhD, Artemio Mojón, PhD, José R. Fernández, PhD and Francesco Portaluppi, MD, PhD (Bioengineering & Chronobiology Laboratories, University of Vigo, Campus Universitario, Vigo, Spain and others)

Chapter 2 - ACEIs as Antihypertensives in African Americans: A 21st Century Perspective (pp. 41-72)
Sandra F. Williams, DMD, MD, Nosratola D. Vaziri, MD, Susanne B. Nicholas, MD, MPH, PhD and Keith C. Norris, MD (Department of Endocrinology, Cleveland Clinic, Weston, FL, USA and others)

Chapter 3 - Angiotensin-Converting Enzyme Inhibitors: A Seattle Internist‘s Perspective (pp. 73-80)
Ngozi Janet Achebe, MD (Capital Medical Center, Olympia, WA, USA)

Chapter 4 - ACEIs in Cardiovascular Medicine: A 21st Century Caribbean Perspective (pp. 81-100)
Pradip Kumar Karmakar, MD, FACC, Dainia Baugh, MD, Felix Nunura, MD, Noel Crooks, MD and Ernest C. Madu, MD, FACC, FRCP (Heart Institute of the Caribbean, Kingston, Jamaica)

Chapter 5 - ACEIs as Antihypertensives: A Nigerian CKD Clinic Experience (pp. 101-128)
Ifeoma I. Ulasi, MD, Chinwuba K. Ijoma, MD, Benedict C. Anisiuba, MD and Ngozi A. Ifebunandu, MD (Renal Unit, Department of Medicine, College of Medicine, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria and others)

Chapter 6 - ACEIs as Antihypertensives in the Elderly (>65 Year Old): A South American Perspective (pp. 129-134)
Carlos G. Musso, MD PhD and Jose Alfie, MD (Hospital Italiano de Buenos Aires, Buenos Aires, Argentina)

Chapter 7 - The Impact of Salt Restriction on the Effectiveness of Antihypertensive Therapy (pp. 135-158)
Natale Gaspare De Santo, MD and Massimo Cirillo, MD (Department of Medicine, Second University of Naples, Naples, Italy and others)

Section 2. ACE Inhibitors and Angiotensin Receptor Blockers in Special Patient Populations

Chapter 8 - Are ARBs the Preferred Agents to Treat Hypertension in Patients with HIV-Nephropathy with Albuminuria? (pp. 161-170)
Biagio Di Iorio, MD, Antonio Bellasi, MD and Giovanni Guaraldi, MD (Department of Nephrology and Dialysis, PO “A Landolfi” – Solofra (AV), Italy and others)

Chapter 9 - The Use of ACEIs and ARBs in ESRD Patients on Maintenance Hemodialysis and Peritoneal Dialysis (pp. 171-191)
Donald A. Molony, MD (Division of Renal Diseases and Hypertension AND Center for Clinical Research and Evidence-based Medicine, University of Texas Houston Medical School, Houston, TX, USA)

Chapter 10 - The Use of Angiotensin-Converting Enzyme Inhibitors in the Renal Transplant Recipient (pp. 192-202)
Matthew R. Weir, MD and Manju Mavanur, MD (Division of Nephrology, University of Maryland School of Medicine Medical Center, Baltimore, MD, USA)

Chapter 11 - ACE Inhibition and Renal Artery Stenosis: What Lessons Have we Learnt? A 21st Century Perspective (pp. 203-218)
Mukesh Singh, MD MRCPI, Daniela Filip Kovacs, MD FACC, Amteshwar Singh, MBBS, Prabhpreet Dhaliwal and Sandeep Khosla, MD FACC (Chicago Medical School, Rosalind Franklin University of Medicine & Sciences, North Chicago, IL, USA and others)

Chapter 12 - Angiotensin-Converting Enzyme Inhibitors in Renal Disease: A European Perspective (pp. 219-242)
Nicolas Roberto Robles, MD (Institute of Cardiovascular Risk, Faculty of Medicine, University of Salamanca, Salamanca, Spain and others)

Chapter 13 - Angiotensin-Converting Enzyme Inhibitors in Heart Failure (pp. 243-248)
Kaushik Guha, MD and R. Sharma, MD (Dept. of Cardiology, Royal Brompton Hospital, Sydney Street, London, UK and others)

Chapter 14 - RAAS Blockade in Ethnic Minorities with Chronic Kidney Disease: A United Kingdom Perspective (pp. 249-262)
Conor Byrne, MD and Muhammad Magdi Yaqoob, MD PhD (Barts Health NHS Trust & William Harvey Research Institute, Queen Mary College, University of London, UK and others)

Chapter 15 - Use of ACE-Inhibitors and Angiotensin-2 Receptor Blockers in the Management of the Cardio-Renal Syndrome (pp. 263-276)
Chike Nathan Okechukwu, MD and Muhammad Tahseen, MD (Department of Medicine, Temple University, Philadelphia, PA, USA and others)

Chapter 16 - A Three-Year Clinical Experience with ACE Inhibitors at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria, Department of Pediatrics, 2010-2012 (pp. 277-284)
Ebele Francesca Ugochukwu, BSc MBBS FWACP[Ped] (Department of Pediatrics, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria)

Chapter 17 - Is There a Role for ACEIs in the ICU? (pp. 285-294)
Pascale Khairallah, MD and Kianoush Kashani, MD (Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA, and others)

Chapter 18 - The Impact of ACE Inhibition in the Management of Sickle Cell Disease in Nigerian Adults (pp. 295-307)
Ademola Aderibigbe, MBBS FMCP FWACP, Fatiu Abiola Arogundade, MBBS FMCP FWACP and Timothy Olanrewaju, MBBS FMCP

Section 3. New and Emerging Indications for ACE Inhibitors and Angiotensin Receptor Blockers

Chapter 19 - Hypertension-Misattributed Kidney Disease in African Americans (pp. 309-322)
Karl Skorecki, MD FRCP(C) FASN and Walter G. Wasser, MD (Rappaport Faculty of Medicine and Research Institute, Technion - Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel and others)

Chapter 20 - Treatment of Infantile Hemangioma with an ACE Inhibitor: A Paradigm Shift (pp. 323-333)
Tinte Itinteang, MBBS PhD, Paul F. Davis, PhD and Swee T. Tan, MBBS FRACS PhD (Gillies McIndoe Research Institute, New Zealand and others)
Free Download Available

Section 4. Epilogue - ACE Inhibitors and Angiotensin Receptor Blockers and Renoprotection revisited: The Future of Renoprotection in the 21st Century

Chapter 21 - Epilogue - Bold Predictions on the Future of Renoprotection: The Way Forward with Multiple Pathway Blockers – Making a Case For Novel Non-Angiotensin Inhibiting Renoprotective Agents like Corticotropin and Pentoxifylline (pp. 335-344)
Macaulay Amechi Onuigbo, MD MSc FWACP FASN MBA (College of Medicine, Mayo Clinic, Rochester, MN, USA and others)

About the Editor

Index

Click here, to read the review by - Dr. Dwomoa Adu, Honorary Consultant Physician, Department of Medicine and Therapeutics, University of Ghana Medical School, Accra, Ghana

You have not viewed any product yet.